Frequency and impact on clinical outcomes of sarcopenia in patients with idiopathic pulmonary fibrosis
Chronic Respiratory Disease · 2022-01 · 19
DOI: 10.1177/14799731221117298 ↗Kurz gefasst
Fachartikel in der Zeitschrift Chronic Respiratory Disease, online erschienen am 05.08.2022. Verfasst von Kohei Fujita und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Medicine, Allergy and Clinical Immunology, 38386Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan. Hauptthemen laut MEDLINE: Idiopathic Pulmonary Fibrosis, Sarcopenia. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Objectives
Sarcopenia is a syndrome characterized by reduced muscle mass and function. It is well-recognized as a complication in chronic diseases such as chronic obstructive pulmonary disease. However, little is known about sarcopenia in patients with idiopathic pulmonary fibrosis (IPF). This study aimed to investigate the clinical characteristics of sarcopenia and the association between quality of life and sarcopenia in patients with IPF.
Methods
In this pilot cross-sectional study, 56 Japanese outpatients with IPF (49 men) were enrolled prospectively. Sarcopenia was diagnosed according to the criteria of the Asian Working Group for Sarcopenia 2019. Its associations with clinical parameters including age, pulmonary functions, physical performance, and patient-reported outcomes (PROs) were examined.
Results
The frequency of sarcopenia was 39.3% ( n = 22) in this cohort. There were significant differences in St George’s Respiratory Questionnaire ( p = .005), modified Medical Research Council score ( p = .004), and Hospital and Anxiety Depression Scale depression score ( p = .030) between the sarcopenic and non-sarcopenic groups. On multivariate regression analysis, 6-min walk distance (6MWD) was an independent factor associated with sarcopenia (odds ratio 1.241, 95% confidence interval 1.016–1.515, p = .034).
Conclusion
Sarcopenia was associated with PROs and physical performance in patients with IPF.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Respiratory Medicine, Allergy and Clinical Immunology, 38386Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
- Department of Respiratory Medicine, 36975Nagoya City University East Medical Center, Nagoya, Japan.
- Department of Radiology, 38386Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
- Department of Pathology and Molecular Diagnostics, 38386Graduate School of Medical Sciences, Nagoya City University, Nagoya, Japan.
ORCID-Profile: Hirotsugu Ohkubo, Ken Maeno
Zitieren
APA
Fujita, K., Ohkubo, H., Nakano, A., Mori, Y., Fukumitsu, K., Fukuda, S., Kanemitsu, Y., Uemura, T., Tajiri, T., Maeno, K., Ito, Y., Oguri, T., Ozawa, Y., Murase, T., & Niimi, A. (2022). Frequency and impact on clinical outcomes of sarcopenia in patients with idiopathic pulmonary fibrosis. Chronic Respiratory Disease, 19. https://doi.org/10.1177/14799731221117298
Vancouver
Fujita K, Ohkubo H, Nakano A, Mori Y, Fukumitsu K, Fukuda S, et al. Frequency and impact on clinical outcomes of sarcopenia in patients with idiopathic pulmonary fibrosis. Chronic Respiratory Disease. 2022;19. doi:10.1177/14799731221117298
BibTeX
@article{Fujita2022,
author = {Fujita, Kohei and Ohkubo, Hirotsugu and Nakano, Akiko and Mori, Yuta and Fukumitsu, Kensuke and Fukuda, Satoshi and Kanemitsu, Yoshihiro and Uemura, Takehiro and Tajiri, Tomoko and Maeno, Ken and Ito, Yutaka and Oguri, Tetsuya and Ozawa, Yoshiyuki and Murase, Takayuki and Niimi, Akio},
title = {Frequency and impact on clinical outcomes of sarcopenia in patients with idiopathic pulmonary fibrosis},
journal = {Chronic Respiratory Disease},
year = {2022},
volume = {19},
doi = {10.1177/14799731221117298}
}
EUVIMED